Uridyl peptide antibiotics display potent activity against Pseudomonas aeruginosa, a pathogen causing severe nosocomial infections. The four subclasses—mureidomycins, pacidamycins, napsamycins, and sansanmycins—inhibit the underexplored bacterial target phospho-MurNAc-pentapeptide translocase (MraY). Structurally, thes...
Panagiota-Hanna Koutsandrea, Richard Sonnengrün, Nils Hauck et al.· Microbial Cell Factories· 0 citations
Mureidomycin A is a uridyl peptide antibiotic with potent bioactivity against the Gram-negative pathogen Pseudomonas aeruginosa. Crucial bottlenecks impeding further drug development include low compound production in native producers and heterologous hosts, as well as the formation of numerous derivatives, which furth...
Panagiota-Hanna Koutsandrea, Richard Sonnengrün, Nils Hauck et al.· Journal of Natural Products· 0 citations
Covering: up to 2026The cofactor S-adenosyl-L-methionine (SAM) plays a key role in the biosynthesis of ribosomally synthesised and post-translationally modified peptide (RiPP) natural products. SAM-dependent enzymes have been shown to catalyse important steps in RiPP biosynthesis, including methylation, desaturation, e...
